February 14, 2025

Higher Medicine has been selected as one of the companies in the Maryland TEDCO SBIR/STTR Proposal Lab 2025 Cohort

Funded by TEDCO and administered by the leading experts in the field, Proposal Lab supports companies in securing competitive and prestigious NSF and other grants to advance their R&D portfolios.

“We are happy to support these 28 companies as they take the initiative and gear up to submit for crucial funding,” said Kim Mozingo, vice president of Federal Programs at TEDCO.

This announcement recognizes Higher Medicine's strategic vision and drug development potential for functional cures targeting rare genetic disorders. With TEDCO's support, Higher Medicine is accelerating toward securing non-dilutive NSF funding to reach value-inflection points more quickly and capital-efficiently.

Learn more at https://lnkd.in/eHi9jpX5

Latest News

Our platform offers a variety of resources to keep you informed about our latest programs, key updates, achievements, and other significant developments in the field of healthcare and medicine.

Company Announcements
June 16, 2025

Higher Medicine Announces a Pre-Seed Builder Fund Investment from TEDCO

TEDCO's Pre-Seed Builder Fund, one of the state's marquee investment vehicles in Maryland, invested in Higher Medicine.

Read more
Company Announcements
June 12, 2025

Higher Medicine Announces Strategic Investment and Clinical Alliance with 5 Horizons Capital to Advance a Clinical Trial

Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.

Read more
Company Announcements
June 2, 2025

Higher Medicine Joins BIO 2025 in Boston as a part of the Maryland Delegation

Higher Medicine attends the 2025 BIO International Convention from June 16–19 in Boston, MA, as part of the official Maryland delegation.

Read more
Company Announcements
June 2, 2025

Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology

Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.

Read more
Company Announcements
April 25, 2025

Higher Medicine Selected for HiveBio Accelerator Cohort

HiveBio Accelerator program offers world-class training, mentorship, and support to help scale Higher Medicine and secure follow-on funding.

Read more
Company Announcements
April 25, 2025

Higher Medicine Secures $500,000 Seed Investment from Desire Ventures

Higher Medicine seed investment secured from Desire Ventures

Read more